Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Erwinia Asparaginase in High-Risk Adults With Newly Diagnosed ALL or LBL
NCT06918431Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2025
- Primary completion
- Mar 2029
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Asparaginase erwinia chrysanthemi in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 28 days, Incidence of unacceptable adverse events at 28 days and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
Asparaginase erwinia chrysanthemi
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT06918431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918431.